Can we achieve complete remission in locally advanced unresectable Hepatocellular Carcinoma (HCC) by using Sorafenib? Case report and review of literature from Qatar
Patients with HCC continue to have a dismal prognosis, with 1-year and 3-year survival rates of 36 and 17%, respectively. This is in part related to more than two-thirds of tumors being diagnosed at advanced stages, as well as a substantial portion of patients with early HCC failing to receive potentially curative treatments. Systemic therapy for advanced unresectable HCC limited until the discovery of sorafenib, we are reporting a 53 year patient with unresectable HCC achieved complete remission clinically, radiologically and biochemically with sorafenib which is the first case report.
References
[1]
El-Serag, H.B., Siegel, A.B., Davila, J.A., et al. (2006) Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: A population-based study. Journal of Hepatology, 44, 158-166. doi:10.1016/j.jhep.2005.10.002
[2]
Josep, M. Llovet, M.D., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., et al. (2008) Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine, 359, 378-390. doi:10.1056/NEJMoa0708857
[3]
Cheng, A.L., Kang, Y.K., Chen, Z., Tsao, C.J., et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. The Lancet Oncology, 10, 25-34. doi:10.1016/S1470-2045(08)70285-7
[4]
Forner, A., Hessheimer, A.J., Isabel Real, M., et al. (2006) Treatment of hepatocellular carcinoma. Critical Reviews in Oncology/Hematology, 60, 89-98. doi:10.1016/j.critrevonc.2006.06.001
[5]
Okuda, K. (2000) Hepatocellular carcinoma. Journal of Hepatology, 32, 225-237. doi:10.1016/S0168-8278(00)80428-6
[6]
Llovet, J.M., Bustamante, J., Castells, A., et al. (1999) Natural history of unresected nonsurgical hepatocellular carcinoma for the design and evaluation of therapeutic trials. Hepatology, 29, 62-67. doi:10.1002/hep.510290145
[7]
Okuda, K., Takayasu, K., Okada, S. (1997) Treatment selection. In: Okuda, K. and Tabor, E. Eds., Liver Cancer, Churchill-Livingstone, New York, 435-439.
